The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12623000665639p
Ethics application status
Submitted, not yet approved
Date submitted
6/06/2023
Date registered
20/06/2023
Date last updated
20/06/2023
Date data sharing statement initially provided
20/06/2023
Type of registration
Prospectively registered

Titles & IDs
Public title
Ketogenic low carbohydrate, high fat diet in marathon runners
Scientific title
The effects of a ketogenic low carbohydrate, high fat diet on performance in endurance marathon runners: a randomized controlled trial
Secondary ID [1] 309845 0
none
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Athletic performance nutrition 330287 0
Body composition 330288 0
Glycaemic control 330289 0
Condition category
Condition code
Diet and Nutrition 327148 327148 0 0
Other diet and nutrition disorders
Physical Medicine / Rehabilitation 327211 327211 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Methodology
Single-blind randomized controlled trial. Competitive marathon runners will be randomized to their usual high carbohydrate diet (comparator) or a ketogenic-low carbohydrate, high fat (K-LCHF) diet (intervention) for 6 months. It will not be possible to blind participants to diet group allocation, but outcome assessors will be blinded to the primary outcome during the performance test. Baseline marathon performance will be assessed in the 2023 Sydney marathon. Post intervention performance will be assessed 12 months later in the 2024 Sydney marathon. This design allows for real-world running performance to be tested with practicable control for season of the year and racecourse effects on running time. After baseline marathon performance is measured, diet and training will be monitored for 6 months leading into the diet randomization (lead-in diet and training monitoring). Baseline marathon performance and baseline and pre randomization aerobic capacity (VO2max), sex, body composition, as well as training characteristics (overall load, low / high intensity training split) assessed during the lead-in, will be used to pair-match participants. Once matched, participants will be randomly assigned (blinded, random number generator method) to follow either their usual high carbohydrate diet (comparator) or a K-LCHF diet (intervention) for the 6 months leading into the 2024 Sydney marathon.

Diet intervention
Before being randomized to a dietary intervention group, diet will be assessed at baseline and at 1-month intervals (diet reporting for 2 weekdays and 1 weekend day on each occasion) over a 6-month period (lead-in diet monitoring) using the diet tracking app, EasyDietDiary (Australian based diet tracking App, password protected login access). This will be done to confirm that participants are following a high carbohydrate diet (i.e., following the Australian dietary guidelines) at baseline and during lead-in to the diet intervention. After randomization, participants in the K-LCHF diet intervention group will receive nutritional counselling and resources to assist in learning how to adhere to a K-LCHF diet. The diet intervention will be delivered online and will involve reviewing a series of modules that have been designed specifically for this study. Modules will cover practical knowledge and skills required to follow the K-LCHF diet, including acceptable food items, shopping and meal preparation suggestions presented as written text, figures, and short videos. A module covering training and competition fuelling strategies that adhere to the principles of a K-LCHF diet will also be provided. Reviewing the online learning modules will take approximately 4 hours over the first 2 weeks of the diet intervention. Learning materials will remain accessible at any time during the 6 month intervention. A ketogenic, low carbohydrate diet is a whole food, nutrient rich diet that avoids grains, starches, refined sugars, and most processed foods. Well-formulated ketogenic diets promote the consumption of meat, chicken, seafood, eggs, dairy, leafy and cruciferous vegetables, avocados, nuts, seeds, and berries. Nutritional counselling and monitoring will be overseen by Associate Professor Caryn Zinn, a Registered Dietitian with more than 15 years’ experience. Participants will be asked to use EasyDietDiary to record all food intake for 7 days every week for the first 4 weeks after randomization, followed by 3 days (2 weekdays and 1 weekend day) every month for the remainder of the study (i.e., weeks;1, 2, 3, 4, months; 2, 3, 4, 5, 6). The K-LCHF diet will be prescriptive with regards to macronutrient intake (70% fat, 20% protein, and the lesser of 20 g or 10% nett carbohydrates) but ad libitum for total calories plus or minus 20% of lead-in caloric intake. Participant EasyDietDiary diet information will be reviewed at the end of each diet monitoring assessment block and participants will be advised if any modifications to macronutrient composition, micronutrient requirements or total caloric intake is required. Suggested meal plans and meal recipes will be formulated by the study dietitian to meet subjects’ micronutrient requirements with special attention to sodium intake because higher sodium losses have been shown to occur during very low carbohydrate intake. Diets that are very low in carbohydrates stimulate the production of ketones (an alternate source of fuel when glucose is low) and ketones are considered a valuable biomarker demonstrating adherence to K-LCHF diets. Participants will self-monitor blood ketones throughout the study (blood finger prick sample) by measuring their blood ketone levels. Participants will be provided with a ketone monitor, ketone strips, alcohol wipes and lancets and asked to take replicate (i.e., two measures for increased reliability) blood ketone measurements once per month during the diet intervention.

Competition fuelling strategy
Participants will be asked to report their marathon race fuelling strategy i.e., the intervals, type, and quantify of fuel consumed during their marathon race. Participants randomized to the K-LCHF diet intervention group will be encouraged to follow the prescriptive diet macronutrient intake (70% fat, 20% protein, and the lesser of 20 g or 10% carbohydrates) on the day of the post intervention marathon race but it may be unreasonable for researchers to enforce this. While it is not unusual for some athletes (even those habitually consuming a standard high carbohydrate diet) to completely avoid carbohydrate consumption during marathon races, unless athletes have previously experimented using a low carbohydrate fuelling strategy, some individuals in this study may not be confident in limiting carbohydrate fuelling during their marathon. To be practical, it is reasonable to accept that an additional carbohydrate allowance during the marathon race, should athletes feel they require it, is in the best interests of the athletes and compatible with the research design. Habitual K-LCHF diet, not marathon race fuelling strategy is the independent variable in this study.

Training and athlete monitoring
We will use questionnaires within a secure password protected App, StackTeamApp (no cost to participants) to monitor athletes training and general health, including any adverse effects during the diet intervention. The App will assist in managing participant scheduling for attending lab testing sessions and sending in App and text reminders to complete research tasks. This approach is designed to minimize the burden on participants for reporting data. Training loads will be tracked throughout the study and reported as training hours, self-reported intensity splits, training pace, and estimated running distances per week. When available, participants can share training metrics measured using GPS tracking watches and measures of heart rate with researchers. The intervention will not include control over athlete training practices (load and structure). Participants will be asked to select and specify a marathon training plan of their choice at the start of the study and follow the same training plan as closely as circumstances allow, before both the 2023 and 2024 Sydney marathons. Participants in this study will be experienced marathon runners and can therefore select any training plan that is compatible with their personalized training approach. Imposing training requirements on experienced marathon runners could affect study outcomes in unexpected ways. For example, it may have unintended negative consequences for recovery, or injury risk, or participant adherence. By having participants report their training plan and carefully monitoring their training practices during the 6-month lead-in phase, and using this information to pair-match participants before randomization, we believe large deviations in training practices at the intervention group level are unlikely. Any differences will be comprehensively measured during the intervention and could be used to better understand variance in individual performances at the end of the trial. Adopting a ketogenic, low carbohydrate diet can be associated with side effects that are usually transient and mild. Common adverse effects, often referred to as “keto flu,” include light-headedness, generalized fatigue, difficulty exercising, poor sleep, and constipation. These typically resolve within days to weeks. Participants can report symptoms or raise concerns any time they feel the need using the StackTeamApp.
Intervention code [1] 326283 0
Treatment: Other
Intervention code [2] 326331 0
Lifestyle
Comparator / control treatment
Competitive marathon runners randomly allocated to the active control will be asked to follow their usual high carbohydrate diet (20% fat, 20% protein, and 60% carbohydrate) and usual training and competition schedule for the 6 months leading into the 2024 Sydney marathon.
Control group
Active

Outcomes
Primary outcome [1] 335019 0
Marathon race time is the primary outcome for this clinical trial. This outcome will be assessed via audit of the official marathon results.
Timepoint [1] 335019 0
Marathon race performances will be measured in a real-world setting of the 2023 (baseline) and 2024 (post intervention) September Sydney Marathon events. The Sydney marathon is a World Athletics Gold Label Marathon.
Secondary outcome [1] 422721 0
Maximal aerobic oxygen consumption (VO2max) measured as absolute L/min and relative mL/kg/min will be assessed in a standard graded treadmill running test using indirect calorimetry breath-by-breath gas analysis (QUARK CPET; COSMED, Rome, Italy).
Timepoint [1] 422721 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [2] 422722 0
Exercise fuel utilization (%fat vs %carbohydrate expressed as the respiratory quotient, a value between 0.7 and 1.0) using indirect calorimetry breath-by-breath gas analysis (QUARK CPET; COSMED, Rome, Italy) will be measured at four different running speeds corresponding to the speed of individually determined race pace and speeds above and below anaerobic threshold.
Timepoint [2] 422722 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [3] 422723 0
Running economy (oxygen cost per km run per kg of body weight) using indirect calorimetry breath-by-breath gas analysis (QUARK CPET; COSMED, Rome, Italy) will be measured at four different running speeds corresponding to the speed of individually determined race pace and speeds above and below anaerobic threshold.
Timepoint [3] 422723 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [4] 422724 0
Body weight measured using digital scales
Timepoint [4] 422724 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [5] 422725 0
Whole-body composition including estimates of fat and lean mass will be measured using dual-energy X-ray absorptiometry (DXA; Medilink Medix DR, 2D-Fan beam, Montpellier, France).
Timepoint [5] 422725 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [6] 422726 0
4-compartment model of body composition that combines DXA measurements with bioelectrical impedance measurements to provide an estimate of muscle protein (i.e. lean mass) that is independent of total body water.
Timepoint [6] 422726 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [7] 422727 0
Comprehensive analysis of blood markers of interest. A finger prick blood sample (fingerstick method) will be collected in Lithium Heparin capillary tubes and used to perform a Lipid Panel analysis (measures total cholesterol (CHOL), high-density lipoprotein cholesterol (HDL), triglycerides (TRIG), low-density lipoprotein cholesterol (LDL), very low-density lipoprotein cholesterol (VLDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST)) and a Comprehensive Metabolic Panel analysis (measures alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), calcium, chloride, creatinine, glucose, potassium, sodium, total bilirubin, total carbon dioxide, total protein, and blood urea nitrogen (BUN)) using Piccolo Xpress blood analyser.
Timepoint [7] 422727 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [8] 422728 0
Finger prick blood analysis during treadmill running tests. Blood glucose will be measured at rest, in recovery, and following each of the 4 exercise stages in running treadmill economy / VO2max test.
Timepoint [8] 422728 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [9] 422729 0
Glucose kinetics measured using continuous glucose monitors. Abbott Freestyle Libre Pro IQ continuous glucose monitors will be attached to the back of the upper arm using the manufacturer's sensor applicator tool and instructions. Each sensor will be worn for up to 14 days. Sensors are scanned by a reader to wirelessly download the glucose data. Participants are not required to regularly download the data and the system also blinds participants to the glucose readings during the study.
Timepoint [9] 422729 0
Assessed at baseline (in the 2 weeks leading up to and including the 2023 Sydney marathon), at diet randomization (in the 1 week leading up to diet randomization and during the first week after diet randomization at 6 months post-baseline), at post-completion of intervention (in the 2 weeks leading up to and including the 2024 Sydney marathon at 12 months post-baseline).
Secondary outcome [10] 422745 0
Resting heart rate measured using a chest strap.
Timepoint [10] 422745 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [11] 422965 0
Anaerobic threshold as a measure of intensity corresponding to a percentage of maximal aerobic capacity will be assessed in a standard graded treadmill running test using indirect calorimetry breath-by-breath gas analysis (QUARK CPET; COSMED, Rome, Italy).
Timepoint [11] 422965 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [12] 422968 0
Finger prick blood analysis during treadmill running tests. Blood ketones will be measured at rest, in recovery, and following each of the 4 exercise stages in running treadmill economy / VO2max test.
Timepoint [12] 422968 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [13] 422969 0
Finger prick blood analysis during treadmill running tests. Blood lactate will be measured at rest, in recovery, and following each of the 4 exercise stages in running treadmill economy / VO2max test.
Timepoint [13] 422969 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [14] 422971 0
Resting blood pressure measured using an automatic sphygmomanometer.
Timepoint [14] 422971 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).
Secondary outcome [15] 423186 0
Exercise heart rate measured using a chest strap.
Timepoint [15] 423186 0
Assessed at baseline (at the time of the 2023 Sydney Marathon), at pre-diet randomization (6 months post-baseline), at 6 weeks post-diet randomization, at post-completion of intervention (12 months post-baseline).

Eligibility
Key inclusion criteria
Competitive marathon runners will be recruited from running clubs in the greater Sydney region in Australia.

To be considered ‘competitive’, runners must have previously competed in a marathon race with evidence of running a sub 4-hour marathon time (recorded within the past 3 years), be currently completing > 3 h/week training, and have > 2 years training experience.

At baseline, runners must be following Australian dietary guidelines for healthy eating which is considered a high carbohydrate diet.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Unable or unwilling to be randomized to either diet group for the 6 month diet intervention.

Unable or unwilling to enter and compete in the 2023 and 2024 Blackmores Sydney marathon.

Unable to participate in their usual training and competition schedules due to an injury or chronic illness at the study baseline.

Currently, or within the previous 12 months, consuming a low carbohydrate, high fat diet.

Unable or unwilling to attend laboratory-based testing sessions at the university laboratories located in Blacktown, NSW.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed from the CI. An off-site co-investigator will use a random number generator method to randomly allocate participants to treatment or control.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Matched-pair design. Baseline marathon performance and baseline and pre randomization aerobic capacity (VO2max), sex, body composition, as well as training characteristics (overall load, low / high intensity training split) assessed during the lead-in, will be used to pair-match participants. Once matched, participants will be randomly assigned (blinded, random number generator method) to treatment or control.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample Size
The required study sample size has been calculated by a biostatistician using the primary outcome measure of marathon running performance (time) for a RCT design with analysis of covariance. We obtained the finishing times for all runners in the 2022 Sydney marathon. We set an upper bound cut-point of eligible study participants needing a sub-4 hour finishing time. Only a small proportion (54 runners) of the total 3445 race finishers had a time less than 2 hours and 50 minutes so we set this as the lower bound time for runners we can reasonably expect to recruit to the study (this would not exclude runners with times faster than this from participating in the study). This produced an average running time of 3 hours and 35 minutes with a standard deviation of 17.5 minutes for the target population. In the 2022 Sydney marathon, 1228 runners had a finishing time of 4 hours or less (i.e., would meet our study inclusion criteria). Using publicly available data, we estimated that approximately 93% of these participants were Australian (1142 Australian runners), we could not however, determine how many reside within the greater Sydney region and would be able to participate in the study, but we expected this to be the majority. We assumed experienced competitive marathon runners would have a high pre-post-race time correlation. Assuming a pre-post correlation of 0.8 and a power of 0.8 and alpha of 0.05, we calculate that a total of 38 participants (19 per group) will allow us to detect a performance difference between groups of 10 minutes. A change of 10 minutes equates to a medium to large effect size. Diet intervention studies typically have a high loss to follow-up. We will assume a 30% attrition rate and over-recruit by an additional 6 participants per group for a total of 50 participants in the study. Based on the above, we estimated that using the sample size (n = 50) we are aiming to recruit approximately 5% of the eligible population.

Main analysis
IBM Statistics SPSS 24 (Illinois, Chicago, USA) will be used for statistical analyses. Independent sample t-tests or Mann Whitney U tests (where data are not normally distributed) will be used to determine differences between usual high carbohydrate, and K-LCKD diet groups at baseline, with the alpha level for significance set at P < 0.05. Effects for each group will be analysed using ANCOVA, with pre-intervention measures included as covariates. As a measure of effect size, partial eta-squared (np2) will be used. Effect sizes were determined as: np2 = 0.01 (small effect), np2 = 0.09 (medium effect), and np2 = 0.25 (large effect) (Cohen 1988). Paired samples t-tests or Wilcoxon signed ranks test (where data are not normally distributed) will be used to examine changes over time within groups, if ANCOVA P value is < 0.05.

Outliers
We will check all data for implausibly low or high measurements which will be excluded if they fall outside of ±4SD of the mean.

Missing data
We will assume missing covariate and moderator data to be missing at random or completely at random. We will impute missing values using multiple imputation by chained equations. Participants with missing primary outcome data will be excluded from main analyses.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 314032 0
University
Name [1] 314032 0
Australian Catholic University
Country [1] 314032 0
Australia
Primary sponsor type
University
Name
Australian Catholic University
Address
40 Edward Street North Sydney,
NSW 2060
Country
Australia
Secondary sponsor category [1] 315928 0
None
Name [1] 315928 0
Address [1] 315928 0
Country [1] 315928 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 313166 0
ACU Human Research Ethics Committee (HREC)
Ethics committee address [1] 313166 0
Ethics committee country [1] 313166 0
Australia
Date submitted for ethics approval [1] 313166 0
06/04/2023
Approval date [1] 313166 0
Ethics approval number [1] 313166 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 127222 0
Dr Tim Hartwig
Address 127222 0
Australian Catholic University
Level 2, 163-167 Albert Rd, Strathfield, NSW 2135
Edward Clancy Building, Office 640.1.29
Country 127222 0
Australia
Phone 127222 0
+61297014355
Fax 127222 0
Email 127222 0
Contact person for public queries
Name 127223 0
Tim Hartwig
Address 127223 0
Australian Catholic University
Level 2, 163-167 Albert Rd, Strathfield, NSW 2135
Edward Clancy Building, Office 640.1.29
Country 127223 0
Australia
Phone 127223 0
+61297014355
Fax 127223 0
Email 127223 0
Contact person for scientific queries
Name 127224 0
Tim Hartwig
Address 127224 0
Australian Catholic University
Level 2, 163-167 Albert Rd, Strathfield, NSW 2135
Edward Clancy Building, Office 640.1.29
Country 127224 0
Australia
Phone 127224 0
+61297014355
Fax 127224 0
Email 127224 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
All of the individual participant data collected during the trial, after de-identification
When will data be available (start and end dates)?
Immediately following publication (anticipated date March 2025), no end date.
Available to whom?
Only researchers who provide a methodologically sound proposal assessed on a case-by-case basis at the discretion of Primary Sponsor.
Available for what types of analyses?
Any purpose.
How or where can data be obtained?
Access subject to approvals by Principal Investigator and Primary Sponsor. Access can be requested by emailing the principal investigator ([email protected]).


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.